Corindus
This article was originally published in Start Up
Executive Summary
Now that percutaneous coronary inverventions (PCIs) outnumber coronary bypass surgeries by nearly four to one, interventional cardiologists are spending significantly more time in the cath lab. Because PCIs are performed using radiological guidance, physicians must wear leaded garments to protect them from radiation exposure during lengthy procedures. The weight of these garments can lead to orthopedic back and joint problems over time. Corindus is addressing the occupational hazards that have accompanied PCI's growth with a remote control catheterization system that enables cardiologists to advance and manipulate interventional devices inside patients' arteries from a safe distance.
You may also be interested in...
Israel, Fertile Land for Device Company Creation
A surprisingly large number of medical device start-ups emerge from Israel, and at the recent In3 (Investment in Innovation) conference sponsored by the Medtech Insight division of Windhover Information Inc. in Brussels, Belgium in late September, a distinguished panel of venture capitalists made sense of the country's unique climate for device innovation. The speakers also had some lessons to offer to fledgling European device companies as well. Taking part in the panel were Avi Molcho, MD, Managing Director, Life Sciences, for Giza Venture Capital, one of Israel's largest venture firms, Zeev Zehavi, VP of Johnson & Johnson Development Corp., responsible for J&J's corporate investments in Europe and Israel, and Yuval Binur, PhD, Chairman of the board of device company creator Accelerated Technologies.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.